Nearly 80% of Doctors Worldwide Mistakenly Believe Nicotine Causes Lung Cancer, Thwarting Efforts to Help One Billion Smokers Quit

Survey of more than 15,000 physicians in 11 countries uncovers need for further education
The Foundation for a Smoke-Free World invites researchers  to propose new analysis & educational programs 
 

  • On average, nearly 77% of doctors mistakenly believe nicotine causes lung cancer and 78% believe it causes atherosclerosis.
  • While on average 87% of doctors at least moderately agree that helping patients quit smoking is a priority, lack of training and nicotine knowledge adversely impacts quitting and harm reduction advice.
  • Encouragingly, on average, more than 80% of physicians surveyed are at least moderately interested in cessation and tobacco harm reduction training.

A significant majority of doctors across the globe mistakenly attributes the negative health consequences of smoking to nicotine, directly jeopardizing advancements made in helping smokers quit, a survey funded by a Foundation for a Smoke-Free World grant has found.

Sermo, an independent platform and leader in actionable healthcare professional insights, surveyed more than 15,000 doctors online in 11 countries (China, Germany, Greece, India, Indonesia, Israel, Italy, Japan, South Africa, United Kingdom, and the United States).

While an average of 87% of doctors at least moderately agree helping patients quit smoking is a priority, it is troubling that on average 74% mistakenly believe nicotine causes a range of illnesses from lung cancer to COPD.

These results raise serious concerns about doctors' ability to equip patients who smoke with the most accurate and effective advice on how to quit. This misperception could account for the fact that on average only about half of the doctors (55% on average) recommend over the counter nicotine replacement therapy to aid patients with smoking reduction or cessation.

"It is imperative that doctors get the proper training to learn the facts about nicotine and tobacco harm reduction options that can help their smoking patients quit," said Dr. Muhammad Ahmed, Director of Health and Science Research, Foundation for a Smoke-Free World. "With more than 7 million smokers dying annually from smoking-related diseases worldwide, many lives can be saved if doctors become more knowledgeable about the cessation tools available."  

Dr. Jed Rose, President and CEO of Rose Research Center (RRC) and co-inventor of the nicotine patch, said, "Patients look to doctors for trusted health advice. Therefore, it is vital that doctors provide accurate, current advice to smokers about the health risks of smoking cigarettes compared to using products that deliver nicotine without combustion."

RRC is a research facility based in Raleigh, NC that specializes in tobacco dependence research, including research on smokers, addiction, smoking cessation, tobacco harm reduction and the use of other tobacco products. RRC is a Foundation for a Smoke-Free World grantee.

Even though there is near unanimity in the healthcare community that combustion, more than nicotine, is what leads to the negative health consequences from smoking, the Doctors' Survey uncovered that:

  • 74% of doctors on average at least moderately agree that nicotine causes lung, bladder and head/neck/gastric cancer;
    • In the United States this figure is 70%
    • In Germany this figure is 78%
    • In China this figure is 86%
    • In Japan this figure is 85%
  • 78% of doctors on average at least moderately agree that atherosclerosis is caused by nicotine; and
  • 76% of doctors on average at least moderately agree that COPD is caused by nicotine.

Although these misperceptions are alarming, on average 81% of the physicians surveyed are at least moderately interested in training focused on smoking cessation and tobacco harm reduction.

The survey, which was conducted in 2022, also found that while doctors' conversations with patients who smoke focus on the health benefits of cutting down or quitting (73% on average, globally) and the health risks of continuing (73% on average, globally), a comparatively small number of physicians - just over half (56% on average, globally) on average - recommend cutting down on the amount of smokable tobacco products and less than half of doctors (48% on average, globally) help patients develop a plan to quit.

The Foundation for a Smoke-Free World invites researchers to submit proposals to further analyze the Doctors' Survey findings and propose programs that would help improve doctors' fluency about smoking cessation and tobacco harm reduction. Researchers interested in submitting a proposal should contact [email protected]. The Doctors' Survey findings can be accessed on the Foundation's website at www.smokefreeworld.org/doctorssurvey2022/. 

About the Foundation for a Smoke-Free World

The Foundation for a Smoke-Free World is an independent, U.S. nonprofit 501(c)(3) grantmaking organization with the purpose of improving global health by ending smoking in this generation. The Foundation supports its mission through three broad categories of work: Health and Science Research; Agricultural Diversification; and Industry Transformation. For more information about the Foundation, please visit www.smokefreeworld.org.

Media Inquiries
For further information, please contact:
Paul Harrison at Actum LLC on [email protected] or +44 7711 976 655, or
Miran Hassan at Actum LLC on [email protected] or +44 7931 004 003.

Photo - https://mma.prnewswire.com/media/2158003/Nicotine_Lung_Cancer_Bar_Chart_37_Infographic.jpg
Photo - https://mma.prnewswire.com/media/2158004/Physicians_Training_Doctors__Survey__2__35_Infographic.jpg


ข่าวLung Cancer+o:editorวันนี้

Nearly 80% of Doctors Worldwide Mistakenly Believe Nicotine Causes Lung Cancer, Thwarting Efforts to Help One Billion Smokers Quit

Survey of more than 15,000 physicians in 11 countries uncovers need for further educationThe Foundation for a Smoke-Free World invites researchers to propose new analysis & educational programs On average, nearly 77% of doctors mistakenly believe nicotine causes lung cancer and 78% believe it causes atherosclerosis. While on average 87% of doctors at least moderately agree that helping patients quit smoking is a priority, lack of training and nicotine knowledge adversely impacts quitting and

วันมะเร็งปอดโลกซึ่งตรงกับวันที่ตรงกับวันท... เสวนาวันมะเร็งปอดโลก: ดูแลปอด ดูแลใจ เพื่อผู้ป่วยมะเร็งปอด — วันมะเร็งปอดโลกซึ่งตรงกับวันที่ตรงกับวันที่ 1 สิงหาคมของทุกปี จัดขึ้นเพื่อรณรงค์ให้คนทั่วโลกห...

Thai Lung Cancer Group (TLCG) organizes t... TLCG organizes the "Innovations for Thai Lung Cancer Patients 2020" with the launch "LungAndMe" — Thai Lung Cancer Group (TLCG) organizes the "Innovations...

Innovations for Thai Lung Cancer Patients... Innovations for Thai Lung Cancer Patients 2020 launch "LungAndMe" — Innovations for Thai Lung Cancer Patients 2020: evolving treatments for lung cancerBri...

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial...

โรงพยาบาลวัฒโนสถ ขอเชิญชวนผู้ที่สนใจตรวจส... โรงพยาบาลวัฒโนสถเชิญชวนตรวจมะเร็งปอดเนื่องในวันงดสูบบุหรี่โลก (Package Lung Cancer Early Detection ) — โรงพยาบาลวัฒโนสถ ขอเชิญชวนผู้ที่สนใจตรวจสุขภาพ "ป้อ...

Registration & Abstract Submission Open for IASLC's 2016 World Conference on Lung Cancer in Vienna

Largest Worldwide Lung Cancer Research Organization Invites Global Collaborators to Attend Registration and abstract submission is now open for the International Association for the Study of Lung Cancer...

Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

Not intended for UK-based media First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer Initiation and first...

Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

Not intended for UK-based media Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1...